ID   HT-1080/hCLDN-2
SY   hCLDN-2/HT1080
DR   Wikidata; Q116049507
RX   PubMed=25118216;
RX   PubMed=27713828;
CC   Population: Caucasian.
CC   Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 5382; IDH1; Simple; p.Arg132Cys (c.394C>T); ClinVar=VCV000375891; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Heterozygous (from parent cell line).
CC   Transfected with: HGNC; 2041; CLDN2.
CC   Transfected with: UniProtKB; P00552; Transposon Tn5 neo.
CC   Derived from site: In situ; Bone, pelvis, acetabulum; UBERON=UBERON_0001269.
DI   NCIt; C3043; Fibrosarcoma
DI   ORDO; Orphanet_2030; Fibrosarcoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_0317 ! HT-1080
SX   Male
AG   35Y
CA   Cancer cell line
DT   Created: 15-12-22; Last updated: 29-06-23; Version: 3
RX   PubMed=25118216; DOI=10.1124/jpet.114.216911;
RA   Li X.-R., Iida M., Tada M., Watari A., Kawahigashi Y., Kimura Y.,
RA   Yamashita T., Ishii-Watabe A., Uno T., Fukasawa M., Kuniyasu H.,
RA   Yagi K., Kondoh M.;
RT   "Development of an anti-claudin-3 and -4 bispecific monoclonal
RT   antibody for cancer diagnosis and therapy.";
RL   J. Pharmacol. Exp. Ther. 351:206-213(2014).
RX   PubMed=27713828; DOI=10.1002/prp2.266;
RA   Hashimoto Y., Kawahigashi Y., Hata T., Li X.-R., Watari A., Tada M.,
RA   Ishii-Watabe A., Okada Y., Doi T., Fukasawa M., Kuniyasu H., Yagi K.,
RA   Kondoh M.;
RT   "Efficacy and safety evaluation of claudin-4-targeted antitumor
RT   therapy using a human and mouse cross-reactive monoclonal antibody.";
RL   Pharmacol. Res. Perspect. 4:e00266.1-e00266.14(2016).